Aequus Biopharma Inc.
This article was originally published in Start Up
Executive Summary
The Genetic Polymer technology around which Aequus Biopharma, a spin-out of Cell Therapeutics, is being formed will allow it to develop long-acting versions of G-CSF, EPO, and other therapeutic proteins. The founders believe these novel molecules will offer more convenient dosing, and not infringe on the patents already covering the therapeutic use of the proteins.
You may also be interested in...
Start-Up Previews (4/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.
Macromolecules & Spec Pharma: The Good News in Drug Delivery
Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.
Start-Up Previews (4/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.